SuperworthRevelation Biosciences EPS REVB
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$6.09
- Fiscal year 2024
- −$11745.16
- −168% on the year before
Revelation Biosciences' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$6.09.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$11745.16 | −168% |
| FY2023 | $17315.76 | n/a |
| FY2022 | −$903477.12 | n/a |
| FY2020 | −$14112.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$6.09 | n/a | n/a | |
| Q1 FY26 | −$18.97 | n/a | n/a | |
| Q3 FY25 | −$49.56 | n/a | −$841.54 | |
| Q2 FY25 | −$196.28 | n/a | −$1916.18 | |
| Q1 FY25 | −$177.38 | n/a | −$8615.46 | |
| Q4 FY24 | −$418.32 | n/a | −$11745.16 | |
| Q3 FY24 | −$1124.20 | n/a | −$22638.28 | |
| Q2 FY24 | −$6895.56 | n/a | −$34873.44 | |
| Q1 FY24 | −$3307.08 | −107% | −$35813.40 | |
| Q4 FY23 | −$11311.44 | n/a | $17315.76 | |
| Q3 FY23 | −$13359.36 | n/a | $10980.48 | |
| Q2 FY23 | −$7835.52 | n/a | −$52671.36 |
Against its peers
Companies in Healthcare nearest Revelation Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| REVBRevelation Biosciences | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Revelation Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.